THE European Medicines Agency has launched new measures to minimise the risk of "rare but serious liver injury" in connection with Esyma (ulipristal acetate) which is used to treat symptoms of uterine fibroids.
Under the new measures patients must have a liver test before, during and after treatment with Esyma, with the drug to be ceased if any abnormalities are found.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Aug 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Aug 18
